Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

manufacturing site

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

- PMLiVE

EMA says Lilly’s Lartruvo should not be prescribed

First time EMA has acted on accelerated approval follow-up

Eli Lilly HQ

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly claims company ahead of more dominant oncology players

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

Eli Lilly HQ

Lilly gets EMA nod for Verzenio in breast cancer

And puts pressure on Pfizer’s market leading Ibrance and Novartis’ Kisqali

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

- PMLiVE

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Another BACE candidate is abandoned, leaving just one remaining in the pipeline

- PMLiVE

Europe’s public-private alliance targets pain management

Innovative Medicines Initiative (IMI) brings pharma together with academia and patient groups in underserved area

Sue Mahony to retire as president of Lilly Oncology

She will continue in her position until August 31

Eli Lilly HQ

Lilly adds AurKa Pharma to oncology buying spree

Lilly is buying back its former drug after just two years

Eli Lilly HQ

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo is developing IL-10 drugs for potential combination with established immunotherapies

- PMLiVE

FDA panel undermines Lilly and Incyte’s baricitinib hopes

Mixed review doesn’t bode well in competitive market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links